Latest Sleep Apnea Treatment News

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

SomnoMed reports a strong start to FY26 with 13.5% revenue growth and confirms the Clayton Sleep Institute as the first US site for its pivotal Rest Assure clinical study, backed by FDA protocol agreement.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed reports a robust Q4 FY25 with 25% revenue growth and a milestone of treating over 1 million patients, while gearing up for significant capacity expansion and clinical advancements.

SomnoMed Limited reported a robust 23.2% revenue increase in Q3 FY25, reaffirming its full-year guidance while actively addressing new US tariffs through potential duty-free exemptions.

SomnoMed Limited prepares to unveil its H1FY25 financial results on February 28, 2025, accompanied by a live investor presentation and Q&A session. The company remains a global leader in sleep apnea treatment solutions.

Fisher & Paykel Healthcare anticipates increased costs from newly imposed US tariffs on imports from Mexico and China, potentially delaying its gross margin recovery timeline but expects no immediate profit impact for FY2025.